What treatments work best for FH? 

For familial hypercholesterolaemia (FH), the most effective treatments involve a combination of high-intensity statins and, if necessary, additional non-statin therapies to lower LDL cholesterol by at least 50% from the baseline. Because FH is a genetic condition that causes the liver to overproduce or fail to clear ‘bad’ cholesterol, lifestyle changes alone are rarely sufficient. Modern UK clinical protocols now include a range of options, including ezetimibe, PCSK9 inhibitors, and inclisiran, to help patients reach their target levels and protect their long-term heart health. 

What We’ll Discuss in This Article 

• Why high-intensity statins remain the first-line treatment for FH. 

• The role of ezetimibe as a secondary therapy for cholesterol absorption. 

• Advanced injectable treatments: PCSK9 inhibitors and Inclisiran. 

• When lipoprotein apheresis (blood filtering) is required for severe cases. 

• Specific dietary and lifestyle adjustments that support medical therapy. 

• Monitoring treatment success: The 50% reduction target. 

• Using the BMI Calculator to support overall cardiovascular risk management. 

First-Line Therapy: High-Intensity Statins 

Statins are the cornerstone of FH treatment in the UK. They work by blocking a specific enzyme in the liver (HMG-CoA reductase) that is responsible for creating cholesterol. For patients with FH, NICE (National Institute for Health and Care Excellence) recommends ‘high-intensity’ statins, such as Atorvastatin or Rosuvastatin, because they are more effective at significantly lowering LDL levels. 

The goal for most patients starting a statin is to achieve at least a 50% reduction in their LDL cholesterol. If a patient experiences side effects, the doctor may trial different types or lower doses combined with other medications. 

Secondary Treatments: Ezetimibe and Bile Acid Sequestrants 

If a statin alone does not lower cholesterol enough, or if the dose cannot be increased due to side effects, a second medication called ezetimibe is often added. 

While statins stop the liver from making cholesterol, ezetimibe works in the digestive system to stop the body from absorbing cholesterol from food and bile. Combining these two medications is often highly effective for FH patients. In some cases, bile acid sequestrants (resins) may also be used, though these are less common in 2026 due to the availability of newer therapies. 

Advanced Injectable Therapies 

For patients who cannot reach their targets with tablets alone, or for those with very high-risk FH, the NHS provides access to advanced injectable treatments. These are typically prescribed through specialist lipid clinics. 

PCSK9 Inhibitors (Alirocumab and Evolocumab) 

These are monoclonal antibodies injected once or twice a month. They work by blocking the PCSK9 protein, which normally destroys the receptors on the liver that clear LDL. By blocking this protein, more receptors stay active, allowing the liver to clear more ‘bad’ cholesterol from the blood. 

Inclisiran 

Inclisiran is a newer type of ‘siRNA’ therapy. It is an injection given only twice a year by a healthcare professional. It works at the genetic level to silence the production of the PCSK9 protein, providing a long-lasting reduction in LDL cholesterol. 

Treatment Type	Administration	How it Works
Statins	Daily Tablet	Blocks cholesterol production in the liver.
Ezetimibe	Daily Tablet	Blocks cholesterol absorption in the gut.
PCSK9 Inhibitors	Fortnightly Injection	Keeps liver receptors active to clear more LDL.
Inclisiran	6-Monthly Injection	Silences the gene that blocks LDL clearance.

Lipoprotein Apheresis 

For the most severe cases of FH, particularly the rare Homozygous form, medications may not be enough. These patients may require lipoprotein apheresis. This is a procedure similar to kidney dialysis, where the patient’s blood is passed through a machine that physically filters out the LDL cholesterol before returning the blood to the body. This is usually performed every one to two weeks at a specialist hospital centre. 

Causes and Triggers for Treatment Adjustment 

A patient’s treatment plan is not static and may be triggered for review based on several clinical factors: 

• Target Not Met: If the LDL remains above 2.6 mmol/L (or 2.0 mmol/L for those with heart disease) after 3 months of statins. 

• Side Effects: Triggers like muscle pain or raised liver enzymes may prompt a switch to a different statin or an injectable. 

• Pregnancy: Statins and most other lipid medications cannot be taken during pregnancy or while breastfeeding, requiring a specialized management plan. 

• New Health Events: A new diagnosis of diabetes or high blood pressure will often trigger a more aggressive cholesterol-lowering target. 

Differentiation: Lifestyle vs. Medical Treatment 

It is important to differentiate between what lifestyle can achieve and what medical treatment is required for a genetic condition like FH. 

Feature	Lifestyle Changes	Medical Therapy (Statins/Injectables)
LDL Reduction	Typically 5% to 15%	Typically 30% to over 60%
Primary Goal	General health and supporting meds.	Overcoming the genetic ‘fault’.
Sustainability	Can be difficult to maintain alone.	Highly consistent once established.
Clinical Need	Essential for everyone.	Mandatory for almost all FH patients.

To Summarise 

The best treatments for FH are those that combine high-intensity statins with a heart-healthy lifestyle to achieve at least a 50% reduction in LDL cholesterol. For many patients, adding ezetimibe or newer injectable therapies like Inclisiran is necessary to reach safe targets. While diet and exercise are vital for overall heart health, medical intervention is essential for managing the genetic cause of FH and preventing premature heart disease. 

If you experience sudden, crushing chest pain, difficulty breathing, or sudden weakness on one side of your body, call 999 immediately. 

You may find our free BMI Calculator helpful for monitoring your health, as maintaining a healthy weight remains a key pillar in reducing the overall workload on your heart. 

Authority Snapshot 

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, and emergency care. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive care across inpatient and outpatient settings. This article provides evidence-based information aligned with the 2026 NICE and NHS clinical guidelines for the pharmacological management of familial hypercholesterolaemia.